Tweet
T-RAY SCIENCE, INC. FILES PROVISIONAL PATENT ON COUNTERFEIT DRUG DETECTOR
[email protected]
SYS-CON Media
Oct. 17, 2008 01:23 PM
NJ
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 10/17/08 -- T-Ray
Science, Inc., ("T-Ray", the "Company") an emerging leader in the
field of TeraHertz ("THz") research, announced today that it has filed
for provisional patent protection with the U.S. Patent and Trade Mark
Office on a Whispering Gallery Mode ("WGM") Resonator.
T-Ray's WGM Resonator is a sensor system used in analyzing samples
for classification, quantification, monitoring and sensing of health
care products, biologics, and tissue samples.
The Company has sponsored Dr. Suren Gigoyan to advance our research on
this technology. T-Ray has already demonstrated proof of concept with
a prototype and are now focused on developing a compact, low cost,
portable device.
The device will allow pharmacists and consumers alike to verify the
authenticity of solid and fluid dosage pharmaceuticals. The counterfeit
drug industry affects millions of people worldwide, particularly in
developing nations. According to the Center for Medicines in the
Public Interest, counterfeit drug sales will reach US $75 billion
globally by 2010, a more than 90 percent increase from 2005.
"T-Ray's THz WGM Resonator can greatly reduce the plague of counterfeit
drugs in the market today," says T-Ray President and CEO Thomas
Braun. "This platform technology will be the basis for the future
development of portable scanning devices that can be used in other
industrial applications."
About T-Ray Science, Inc.
T-Ray Science, Inc. is a device-to-system technology development
company that seeks to harness the power of TeraHertz radiation, the
last unexplored region of the electromagnetic spectrum. The Company
is involved in the design, innovation and commercialization of THz
based products.
About Dr. Suren Gigoyan
Dr. Suren Gigoyan is working at the University of Waterloo as a
Visiting Scientist with other T-Ray researchers. Dr. Gigoyan is a
Fulbright Scholar and Head of the Millimeter and Microwave Laboratory,
Institute of Radiophysics & Electronics at the Armenian National
Academy of Sciences. He was recently awarded a $240,000 grant from the
government of Canada for research in his native Armenia. This grant
was awarded through the International Science and Technology Center,
a nonproliferation program established by international agreement
in 1992.
Forward Looking Statements
This release contains forward-looking statements, including, but
not limited to, statements regarding the future commercialization
of THz based products, the market demand for these products and the
proprietary protections that the Company will obtain with regard to
the technology, all of which statements are subject to market risks,
and the possibility that the Company will not be able to obtain patent
protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ
from those projected due to a number of risks and uncertainties. The
Company does not undertake to update forward-looking statements in
this news release to reflect actual results, changes in assumptions
or changes in other factors affecting such forward-looking information.
[email protected]
SYS-CON Media
Oct. 17, 2008 01:23 PM
NJ
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 10/17/08 -- T-Ray
Science, Inc., ("T-Ray", the "Company") an emerging leader in the
field of TeraHertz ("THz") research, announced today that it has filed
for provisional patent protection with the U.S. Patent and Trade Mark
Office on a Whispering Gallery Mode ("WGM") Resonator.
T-Ray's WGM Resonator is a sensor system used in analyzing samples
for classification, quantification, monitoring and sensing of health
care products, biologics, and tissue samples.
The Company has sponsored Dr. Suren Gigoyan to advance our research on
this technology. T-Ray has already demonstrated proof of concept with
a prototype and are now focused on developing a compact, low cost,
portable device.
The device will allow pharmacists and consumers alike to verify the
authenticity of solid and fluid dosage pharmaceuticals. The counterfeit
drug industry affects millions of people worldwide, particularly in
developing nations. According to the Center for Medicines in the
Public Interest, counterfeit drug sales will reach US $75 billion
globally by 2010, a more than 90 percent increase from 2005.
"T-Ray's THz WGM Resonator can greatly reduce the plague of counterfeit
drugs in the market today," says T-Ray President and CEO Thomas
Braun. "This platform technology will be the basis for the future
development of portable scanning devices that can be used in other
industrial applications."
About T-Ray Science, Inc.
T-Ray Science, Inc. is a device-to-system technology development
company that seeks to harness the power of TeraHertz radiation, the
last unexplored region of the electromagnetic spectrum. The Company
is involved in the design, innovation and commercialization of THz
based products.
About Dr. Suren Gigoyan
Dr. Suren Gigoyan is working at the University of Waterloo as a
Visiting Scientist with other T-Ray researchers. Dr. Gigoyan is a
Fulbright Scholar and Head of the Millimeter and Microwave Laboratory,
Institute of Radiophysics & Electronics at the Armenian National
Academy of Sciences. He was recently awarded a $240,000 grant from the
government of Canada for research in his native Armenia. This grant
was awarded through the International Science and Technology Center,
a nonproliferation program established by international agreement
in 1992.
Forward Looking Statements
This release contains forward-looking statements, including, but
not limited to, statements regarding the future commercialization
of THz based products, the market demand for these products and the
proprietary protections that the Company will obtain with regard to
the technology, all of which statements are subject to market risks,
and the possibility that the Company will not be able to obtain patent
protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ
from those projected due to a number of risks and uncertainties. The
Company does not undertake to update forward-looking statements in
this news release to reflect actual results, changes in assumptions
or changes in other factors affecting such forward-looking information.